drugset / Trial / NCT00069446

A Study Evaluating Topical Recombinant Human Vascular Endothelial Growth Factor (Telbermin) for Induction of Healing of Chronic, Diabetic Foot Ulcers

NCT00069446 ↗

Phase 1 Completed 50 enrolled Genentech, Inc.
Treatment

Summary

This is a Phase I, double blind, randomized, placebo-controlled study that will enroll approximately 50 adult subjects with Type 1 or Type 2 diabetes mellitus and chronic, diabetic foot ulcers. The study will be conducted at approximately 12 investigational sites in the United States.

Timeline

Start
2003-08
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject sNN0029 Unknown — Topical

Indications